Anteris Technologies to Present at Investor Conferences
AN Australian-based company, Anteris Technologies Global Corp. (AVR), which specializes in structural heart solutions, is gearing up for two significant healthcare investor conferences. Their Chief Executive Officer, Wayne Paterson, is scheduled to present at the 45th Annual TD Cowen Healthcare Conference and the Barclays 27th Annual Global Healthcare Conference. This marks a vital opportunity for Anteris to highlight their innovative DurAVR® Transcatheter Heart Valve (THV), a groundbreaking solution in cardiac care.
Conference Details for TD Cowen
The details for the TD Cowen Healthcare Conference are as follows:
Conference Overview
Date: March 5, 2025 (US time)
Format: Fireside chat with analyst, Joshua Jennings, and one-on-one meetings.
Time: 9:10-9:40 AM (US EST)
Room: Provincetown, 4th Floor
Location: Marriott Copley Plaza, Boston, MA.
Participation in Panel Discussion
In addition to the presentation, Anteris' Chief Medical Officer, Dr. Chris Meduri, will participate in a panel discussion dedicated to Structural Heart-TAVR, moderating the session alongside analyst Joshua Jennings.
Barclays Conference Insights
Following the TD Cowen event, Anteris will also engage at the Barclays Global Healthcare Conference:
Barclays Conference Details
Date: March 11, 2025 (US time)
Format: Fireside chat with analyst, Matt Miksic, and one-on-one meetings.
Time: 9:00-9:25 AM (US EST)
Room: Americana 3 (Track 3)
Location: Loews Miami Beach, Miami, FL.
Accessing the Webcasts
Both webcasts from the TD Cowen and Barclays events will be accessible through the Investor Center section on the Anteris website. This provides an opportunity for those unable to attend the live events to catch up on the latest advancements in Anteris' heart valve technology, including the DurAVR® THV.
About Anteris Technologies
Anteris Technologies Global Corp. is committed to enhancing heart health through innovative medical devices. Their pioneering product, the DurAVR® Transcatheter Heart Valve, is designed specifically for treating aortic stenosis and mimics a healthy aortic valve's function. With a foundation in Australia and a strong presence in Minneapolis, Anteris stands out as a leader in heart valve technology.
Technological Innovations
The DurAVR® THV is the first biomimetic valve of its kind, developed with input from leading interventional cardiologists and cardiac surgeons. Anteris leverages its patented ADAPT® tissue technology, recognized for its clinical safety and efficacy used in numerous patients worldwide. The system combines the valve and delivery technology, showing the potential for improving patient outcomes in heart surgeries.
Commitment to Advancements
As Anteris continues its dedication to developing advanced medical devices, it remains committed to growth and innovation, striving to enhance healthcare in cardiovascular treatment globally.
Frequently Asked Questions
What is Anteris Technologies known for?
Anteris Technologies specializes in structural heart solutions, developing innovative cardiac devices, including the DurAVR® THV.
When and where are the upcoming conferences?
The upcoming conferences are on March 5, 2025, at TD Cowen in Boston, MA, and March 11, 2025, at Barclays in Miami, FL.
How can I access the conference webcasts?
The webcasts can be accessed via the Investor Center on the Anteris website for those who cannot attend in person.
What technology does Anteris use in its heart valves?
Anteris uses ADAPT® tissue technology in its heart valves, which offers a biocompatible and durable solution for valve replacement.
What is the DurAVR® Transcatheter Heart Valve?
The DurAVR® THV is a biomimetic heart valve designed to treat aortic stenosis, mimicking the natural function of a healthy aortic valve.
